TOP
STORY

Researchers investigated the role of prostate leucine zipper (PrLZ) in docetaxel resistance in prostate cancer (PCa), focusing on PrLZ-regulating autophagy pathway. Human PCa PC3, LNCaP and C4-2 cell lines were used as the model system in vitro and PCa xenografts and PrLZ-knockout mice were used as the model system in vivo. [Theranostics]
Full Article

Investigators profiled the mutational spectrum of 32 significantly prostate cancer-associated genes by using disease-targeted sequencing, and found that KMT2D was highly mutated in Chinese patients. [Oncogene]
Full Article

The authors report DBC1 as a key regulator of AR-V7 transcriptional activity and stability in castration-resistant prostate cancer (CRPC) cells. DBC1 functioned as a coactivator for AR-V7 and was required for the expression of AR-V7 target genes including CDH2, a mesenchymal marker linked to CRPC progression. [Oncogene]
Abstract

To evaluate the role of extracellular vesicles (EVs) in the cellular microenvironment, scientists have treated the normal epithelial prostate cell lines, RWPE-1 and PNT-2, with a pool of EVs from biopsies of prostate primary tumors, biopsies of benign prostate hyperplasia, plasma of prostate cancer patients or plasma of healthy individuals. [Mol Carcinog]
Abstract

With continuous progress over the past few decades in understanding diagnosis, treatment, and genetics, much has been learned about the prostate cancer-diagnosed genome. [Prostate Cancer Prostatic Dis]
Abstract

Visit our
reviews
page to see a complete list of reviews in
the prostate cell research field.

A $1 million grant from Gateway for Cancer Research will help Rutgers Cancer Institute of New Jersey Urologic Oncology Chief Isaac Yi Kim, MD, PhD, MBA evaluate the impact of surgically removing the prostate in men with metastatic prostate cancer in the United States and Asia. [Rutgers Cancer Institute]
Press Release

Trovagene, Inc. announced the filing of its protocol for a Phase II clinical trial of PCM-075 in combination with abiraterone acetate, for metastatic castration-resistant prostate cancer (mCRPC) has been submitted to the FDA for review. [Trovagene, Inc.]
Press Release

Janssen Biotech, Inc. announced that the FDA has granted Priority Review designation for the New Drug Application for apalutamide, an investigational, next-generation oral androgen receptor inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer. [Janssen Biotech, Inc.]
Press Release

The Dutch publishing giant Elsevier has granted uninterrupted access to its paywalled journals for researchers at around 200 German universities and research institutes that had refused to renew their individual subscriptions at the end of 2017. [Nature News]
Editorial

Cancer researchers were nervous about who President Donald Trump would choose to replace Harold Varmus as director of the National Cancer Institute (NCI). But their fears of an unconventional candidate proved unfounded when he tapped Norman “Ned” Sharpless. Sharpless, 51, who was then director of the Lineberger Comprehensive Cancer Center at the University of North Carolina in Chapel Hill. [ScienceInsider]
Editorial

Elizabeth Blackburn, the Nobel Prize–winning molecular biologist who took over just two years ago as president of the Salk Institute for Biological Studies in San Diego, California, announced her intent to retire this summer. The unexpected news comes as Salk faces gender discrimination lawsuits from three veteran female scientists and Blackburn herself has been challenged for not moving quickly enough to change what one plaintiff’s suit called an “old boys club” at the renowned research institute. [ScienceInsider]
Editorial